These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 22416801

  • 1. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H, Klotz L.
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
    Boccon-Gibod L, Iversen P, Persson BE.
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Degarelix: a new approach for the treatment of prostate cancer.
    Persson BE, Kold Olesen T, Jensen JK.
    Neuroendocrinology; 2009 Dec; 90(3):235-44. PubMed ID: 19602868
    [Abstract] [Full Text] [Related]

  • 9. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
    Kirby RS, Fitzpatrick JM, Clarke N.
    BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
    Ozono S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y, Takeda K, Ohashi Y, Tsukamoto T, Naito S, Akaza H.
    Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
    [Abstract] [Full Text] [Related]

  • 16. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer.
    Anderson J.
    Future Oncol; 2009 May; 5(4):433-43. PubMed ID: 19450172
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
    Crawford ED, Tombal B, Keane T, Boccardo F, Miller K, Shore N, Moul JW, Damber JE, Collette L, Persson BE.
    Scand J Urol; 2018 May; 52(5-6):349-357. PubMed ID: 30624128
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.